Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples